drugset / Trial / NCT05970224

A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

NCT05970224 ↗

Phase 2 Active not recruiting 23 enrolled Bioxodes S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.

Timeline

Start
2023-11-17
Primary completion
2026-03-20
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ir-CPI Unknown — Intravenous